Lipella Pharmaceuticals (LIPO) Investor Place·2024-07-29 12:20Group 1 - Lipella Pharmaceuticals' stock is experiencing significant gains following an update on its Phase 2a clinical trial for LP-310, aimed at treating Oral Lichen Planus (OLP), a condition affecting over 6 million Americans without an FDA-approved treatment [1][4]. - The CEO of Lipella Pharmaceuticals, Dr. Jonathan Kaufman, expressed satisfaction with the rapid site activation and initial patient enrollment, highlighting this as a crucial milestone for both the company and the patient community [2][4]. - The clinical trial is currently active, with patient recruitment ongoing across multiple sites, indicating progress in the study [4]. Group 2 - The trading volume for LIPO shares has surged, with over 41 million shares traded, compared to a daily average of approximately 46,000 shares [5]. - As of Monday morning, LIPO stock has increased by 145.8%, reflecting strong market interest [6].